INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION

被引：0
|
作者：
Forns, X. [1 ,2 ]
Samuel, D. [3 ]
Mutimer, D. [4 ,5 ]
Fagiouli, S. [6 ]
Navasa, M. [7 ]
Agarwal, K. [8 ]
Berenguer, M. [9 ,10 ]
Colombo, M. [11 ]
Herzer, K. [12 ]
Nevens, F. [13 ]
Van Solingen-Ristea, R. [14 ]
Luo, D. [14 ]
Dierynck, I. [15 ]
Witek, J. [15 ]
机构：
[1] CIBEREHD, Liver Unit, Hosp Clin, Barcelona, Spain
[2] IDIBAPS, Barcelona, Spain
[3] Univ Paris South Villejuif, Hosp Paul Brousse, Ctr Hepatobiliaire, Paris, France
[4] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[5] NIHR BRU, Birmingham, W Midlands, England
[6] Papa Giovanni XXIII Hosp, Gastroenterol & Transplant Hepatol, Bergamo, Italy
[7] Hosp Clin Barcelona, Liver Unit, Barcelona, Spain
[8] Kings Coll Hosp London, London, England
[9] Hosp La Fe, E-46009 Valencia, Spain
[10] CIBEREHD, Valencia, Spain
[11] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[12] Univ Hosp Essen, Liver Transplantat Unit, Essen, Germany
[13] Univ Hosp KU Leuven, Leuven, Belgium
[14] Janssen Res & Dev LLC, Titusville, NJ USA
[15] Janssen Infect Dis BVBA, Beerse, Belgium
来源：
JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1185
引用
收藏
页码：S481 / S481
页数：1
相关论文
共 50 条
  • [21] MALACHITE-I: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir plus /- Ribavirin or Telaprevir plus Peginterferon/Ribavirin in Treatment-Naive Adults With HCV Genotype 1
    Conway, Brian
    Janczewska, Ewa
    Luo, Yan
    Curescu, Manuela
    Greenbloom, Susan
    Streinu-Cercel, Adrian
    Caruntu, Florin A.
    Ghesquiere, Wayne
    Knysz, Brygida
    Mazur, Wlodzimierz
    Fuster, Francisco
    Motoc, Adriana
    Soza, Alejandro
    Arama, Victoria
    Dalgard, Olav
    Sullivan, Danielle
    Liu, Xuan
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2015, 148 (04) : S1001 - S1002
  • [22] MALACHITE-I: PHASE 3B TRIAL OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR plus /- RIBAVIRIN OR TELAPREVIR plus PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE ADULTS WITH HCV GENOTYPE 1
    Conway, B.
    Janczewska, E.
    Luo, Y.
    Curescu, M.
    Greenbloom, S.
    Streinu-Cercel, A.
    Caruntu, F. A.
    Ghesquiere, W.
    Knysz, B.
    Mazur, W.
    Fuster, F.
    Motoc, A.
    Soza, A.
    Arama, V.
    Dalgard, O.
    Sullivan, D.
    Liu, X.
    Podsadecki, T.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S653 - S654
  • [23] Clinical virology findings from treatment-naive and treatment-experienced genotype 1 HCV patients receiving telaprevir/peginterferon/ribavirin in Phase 3 clinical trials
    Kieffer, T. L.
    De Meyer, S.
    Bartels, D. J.
    Sullivan, J. C.
    Dierynck, I.
    Adda, N.
    Kwong, A.
    Jacobson, I. M.
    Sherman, K. E.
    Zeuzem, S.
    Picchio, G.
    ANTIVIRAL THERAPY, 2011, 16 : A27 - A27
  • [24] SIMEPREVIR PLUS SOFOSBUVIR WITH/WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL-RESPONDER/TREATMENT-NAIVE PATIENTS (COSMOS STUDY): PRIMARY ENDPOINT (SVR12) RESULTS IN PATIENTS WITH METAVIR F3-4 (COHORT 2)
    Lawitz, E.
    Ghalib, R.
    Rodriguez-Torres, M.
    Younossi, Z. M.
    Corregidor, A.
    Sulkowski, M. S.
    DeJesus, E.
    Pearlman, B.
    Rabinovitz, M.
    Gitlin, N.
    Lim, J. K.
    Pockros, P. J.
    Fevery, B.
    Lambrecht, T.
    Ouwerkerk-Mahadevan, S.
    Callewaert, K.
    Symonds, W. T.
    Picchio, G.
    Lindsay, K.
    Beumont-Mauviel, M.
    Jacobson, I. M.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S524 - S524
  • [25] Daclatasvir and Asunaprevir in Non-Japanese Asian Patients With Chronic HCV Genotype 1b Infection who are Ineligible for or Intolerant to Interferon-alfa Therapies With or Without Ribavirin: Phase 3 SVR12 Interim Results
    Wei, Lai
    Zhang, Mingxiang
    Xu, Min
    Chuang, Wan-Long
    Lu, Wei
    Xie, Wen
    Jia, Zhansheng
    Gong, Guozhong
    Li, Yueqi
    Bae, Si Hyun
    Yang, Yong-Feng
    Xie, Qing
    Lin, Shumei
    Chen, Xinyue
    Niu, Junqi
    Jia, Jidong
    Garimella, Tushar
    Torbeyns, Anne
    McPhee, Fiona
    Treitel, Michelle
    Yin, Philip
    Mo, Ling
    HEPATOLOGY, 2015, 62 (06) : 1391A - 1391A
  • [26] Telaprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with genotype 1 HCV and mild to moderate liver disease
    Zeuzem, Stefan
    DeMasi, Ralph
    Foster, Graham R.
    Buti, Maria
    Laeuffer, Joerg M.
    Luo, Donghan
    Witek, James
    Rizzetto, Mario
    HEPATOLOGY, 2013, 58 : 1129A - 1129A
  • [27] INTERFERON α-2B BY CONTINUOUS SUBCUTANEOUS INFUSION IN COMBINATION WITH RIBAVIRIN FOR TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS: 12 WEEK INTERIM ANALYSIS
    Muir, Andrew J.
    Bacon, Bruce R.
    Gitlin, Norman
    Kugelmas, Marcelo
    Tillman, Hans L.
    Grovender, Eric A.
    Van Antwerp, Bill
    Mische, Sarah
    Kwo, Paul Y.
    HEPATOLOGY, 2011, 54 : 1439A - 1439A
  • [28] Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive HCV-Genotype 1 or 4 Subjects: Phase 2b COMMAND-1 SVR12 Results
    Hezode, Christophe
    Hirschfield, Gideon M.
    Ghesquiere, Wayne
    Sievert, William
    Rodriguez-Torres, Maribel
    Shafran, Stephen D.
    Thuluvath, Paul J.
    Tatum, Harvey A.
    Waked, Imam
    Esmat, Gamal E.
    Lawitz, Eric
    Rustgi, Vinod K.
    Pol, Stanislas
    Weis, Nina
    Pockros, Paul
    Bourliere, Marc
    Serfaty, Lawrence
    Vierling, John M.
    Fried, Michael W.
    Weiland, Ola
    Brunetto, Maurizia R.
    Everson, Gregory T.
    Zeuzem, Stefan
    Kwo, Paul Y.
    Sulkowski, Mark S.
    Brau, Norbert
    Wind-Rotolo, Megan
    Liu, Zhaohui
    Hughes, Eric A.
    Schnittman, Steven M.
    Yin, Philip D.
    HEPATOLOGY, 2012, 56 : 553A - 554A
  • [29] FINAL SVR24 DATA FROM THE PHASE 3 C-EDGE TREATMENT-NAIVE STUDY OF ELBASVIR (EBR)/GRAZOPREVIR (GZR) IN PATIENTS WITH CHRONIC HCV GENOTYPE 1, 4 OR 6 INFECTION
    Zeuzem, S.
    Ghalib, R.
    Reddy, K. R.
    Pockros, P.
    Ari, Z. B.
    Zhao, Y.
    Brown, D.
    DiNubile, M.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Butterton, J.
    Martin, E.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S821 - S821
  • [30] Sustained Virologic Response (SVR12) in HCV Genotype 1 Patients Receiving Peginterferon Lambda in Combination With Ribavirin and Either Daclatasvir or Asunaprevir: Interim Results From the D-LITE Study
    Vierling, John M.
    Lataillade, Max
    Gane, Edward J.
    Lueth, Stefan
    Serfaty, Lawrence
    Taliani, Gloria
    Rustgi, Vinod K.
    Pol, Stanislas
    Diago, Moises
    Brunetto, Maurizio R.
    Rodriguez-Torres, Maribel
    Bruce, Robert D.
    Sola, Ricard
    Zeuzem, Stefan
    Gordon, Stuart C.
    Cohen, David S.
    Horga, Arantxa
    Srinivasan, Subasree
    Lopez-Talavera, Juan Carlos
    HEPATOLOGY, 2012, 56 (06) : 1522 - 1523
12345